8 results on '"Armiger N"'
Search Results
2. Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients
- Author
-
Miguel A. González-Gay, María Carmen Cenit, Mario Martínez-Florensa, Carles Tolosa, Noelia Armiger, Ana Suárez, Francisco Hernandez, Elena Carnero-Montoro, Javier Martín, Francisco Lozano, Norberto Ortego-Centeno, Enrique de Ramón, Elena Bosch, Miguel Caballero-Baños, M.T. Arias, José Mario Sabio, Daniel Benitez, Marta Consuegra, Lizette Bonet, Universidad de Cantabria, Universitat de Barcelona, Ministerio de Economía y Competitividad (España), Generalitat de Catalunya, Junta de Andalucía, European Commission, Instituto de Salud Carlos III, [Cenit,MC, Martín,J] Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain. [Martínez-Florensa,M] ImmunNovative Developments, Barcelona, Spain. [Martínez-Florensa,M, Consuegra,M, Bonet,L, Armiger,N, Benitez,D, Lozano,F] Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Carnero-Montoro,E, Bosch,L] Institut de Biologia Evolutiva (CSIC-Universitat Pompeu Fabra), Departament de Ciències Experimentals i de la Salut, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain. [Caballero-Baños,M, Arias,MT, Lozano,F] Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain. [Ortego-Centeno,N] Department of Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain. [de Ramón,E] Department of Internal Medicine, Hospital Carlos Haya, Málaga, Spain. [Sabio,JM] Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Spain. [García–Hernández,FJ] Department of Internal Medicine, Hospital Virgen del Rocío, Seville, Spain. [Tolosa,C] Department of Internal Medicine, Hospital Parc Taulí, Sabadell, Spain. [Suárez,A] Department of Functional Biology, Immunology Area, Faculty of Medicine, University of Oviedo, Oviedo, Spain. [González-Gay,MA] Department of Rheumatology, Hospital Marques de Valdecilla, IFIMAV, Santander, Spain. [Lozano,F] Departament de Biologia Cel•lular, Immunologia i Neurociencies, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain., and This work was supported by grants from the Spanish Ministerio de Economía y Competitividad [SAF2010-19717 to FL, SAF2009-11110 to JM, SAF2011-29239, and BFU2008-01046 to EB], Generalitat de Catalunya [2009SGR00252 to FL, and 2009SGR1101 to EB], Junta de Andalucı´a [CTS-4977], and Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional/FEDER [RD12/0009/0004 to JM]
- Subjects
Phenomena and Processes::Immune System Phenomena::Immunity::Autoimmunity [Medical Subject Headings] ,Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis [Medical Subject Headings] ,T-Lymphocytes ,Lymphocyte ,Lupus nephritis ,Polimorfismo genético ,Autoimmunity ,Lymphocyte Activation ,medicine.disease_cause ,Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypes [Medical Subject Headings] ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,immune system diseases ,Nefritis lúpica ,Medicine and Health Sciences ,Lupus Erythematosus, Systemic ,Immunologia ,Lymphocytes ,Genetics ,Multidisciplinary ,Estudios de casos y controles ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings] ,Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic [Medical Subject Headings] ,Predisposición genética a la enfermedad ,Lupus Nephritis ,Humanos ,medicine.anatomical_structure ,Medicine ,Haplotipos ,Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings] ,Alelos ,Nephritis ,Research Article ,Genotype ,Inflammatory Diseases ,T cell ,Science ,Immunology ,Antígenos CD5 ,Single-nucleotide polymorphism ,Autoinmunidad ,CD5 Antigens ,Limfòcits ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings] ,Rheumatology ,Lupus eritematós sistèmic ,Lupus eritematoso sistémico ,medicine ,Humans ,Genetic Predisposition to Disease ,Allele ,Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Alleles [Medical Subject Headings] ,Alleles ,Polymorphism, Genetic ,Lupus erythematosus ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Antigens, CD58 [Medical Subject Headings] ,business.industry ,Haplotype ,Biology and Life Sciences ,Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic [Medical Subject Headings] ,medicine.disease ,Haplotypes ,Case-Control Studies ,Lupus eritematós ,business ,Genotipo - Abstract
Cénit, M.C. et al., CD5 plays a crucial role in autoimmunity and is a well-established genetic risk factor of developing RA. Recently, evidence of positive selection has been provided for the CD5 Pro224-Val471 haplotype in East Asian populations. The aim of the present work was to further analyze the functional relevance of non-synonymous CD5 polymorphisms conforming the ancestral and the newly derived haplotypes (Pro224-Ala471 and Pro224-Val471, respectively) as well as to investigate the potential role of CD5 on the development of SLE and/or SLE nephritis, This work was supported by grants from the Spanish Ministerio de Economía y Competitividad [SAF2010-19717 to FL, SAF2009-11110 to JM, SAF2011-29239, and BFU2008-01046 to EB], Generalitat de Catalunya [2009SGR00252 to FL, and 2009SGR1101 to EB], Junta de Andalucía [CTS-4977], and Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional/FEDER [RD12/0009/0004 to JM].
- Published
- 2014
3. Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.
- Author
-
Giménez-Capitán A, Sánchez-Herrero E, Robado de Lope L, Aguilar-Hernández A, Sullivan I, Calvo V, Moya-Horno I, Viteri S, Cabrera C, Aguado C, Armiger N, Valarezo J, Mayo-de-Las-Casas C, Reguart N, Rosell R, Provencio M, Romero A, and Molina-Vila MA
- Subjects
- Humans, Protein-Tyrosine Kinases genetics, Anaplastic Lymphoma Kinase genetics, RNA genetics, Proto-Oncogene Proteins c-ret genetics, Proto-Oncogene Proteins genetics, Liquid Biopsy, Oncogene Proteins, Fusion genetics, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung diagnosis, Lung Neoplasms pathology, Cell-Free Nucleic Acids
- Abstract
ALK, ROS1, and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non-small-cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often the only material available. In this study, circulating-free RNA (cfRNA) and extracellular vesicle RNA (EV-RNA) were purified from liquid biopsies. Fusion and MET∆ex14 transcripts were analyzed by nCounter (Nanostring) and digital PCR (dPCR) using the QuantStudio
® System (Applied Biosystems). We found that nCounter detected ALK, ROS1, RET, or MET∆ex14 aberrant transcripts in 28/40 cfRNA samples from positive patients and 0/16 of control individuals (70% sensitivity). Regarding dPCR, aberrant transcripts were detected in the cfRNA of 25/40 positive patients. Concordance between the two techniques was 58%. Inferior results were obtained when analyzing EV-RNA, where nCounter often failed due to a low amount of input RNA. Finally, results of dPCR testing in serial liquid biopsies of five patients correlated with response to targeted therapy. We conclude that nCounter can be used for multiplex detection of fusion and MET∆ex14 transcripts in liquid biopsies, showing a performance comparable with next-generation sequencing platforms. dPCR could be employed for disease follow-up in patients with a known alteration. cfRNA should be preferred over EV-RNA for these analyses., (© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)- Published
- 2023
- Full Text
- View/download PDF
4. Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
- Author
-
Casadó-Llombart S, Ajami T, Consuegra-Fernández M, Carreras E, Aranda F, Armiger N, Alcaraz A, Mengual L, and Lozano F
- Subjects
- Antigens, CD genetics, Antigens, Differentiation, T-Lymphocyte, CD5 Antigens, Cell Adhesion genetics, Humans, Lymphocyte Activation, Male, T-Lymphocytes, Tumor Microenvironment, Activated-Leukocyte Cell Adhesion Molecule genetics, Prostatic Neoplasms genetics
- Abstract
Background: The view of prostate cancer (PCa) progression as a result of the interaction of epithelial cancer cells with the host's immune system is supported by the presence of tumor infiltrating lymphocytes (TILs). TILs fate and interaction with the tumor microenvironment is mediated by accessory molecules such as CD5 and CD6, two signal-transducing coreceptors involved in fine-tuning of T cell responses. While the nature of the CD5 ligand is still controversial, CD6 binds CD166/ALCAM, a cell adhesion molecule involved in progression and dissemination of epithelial cancers, including PCa. The purpose of the present study was to determine the role of CD5, CD6, and CD166/ALCAM gene variants in PCa., Methods: Functionally relevant CD5 (rs2241002 and rs2229177), CD6 (rs17824933, rs11230563, and rs12360861) and CD166/ALCAM (rs6437585, rs579565, rs1044243, and rs35271455) single nucleotide polymorphisms (SNPs) were genotyped in germline DNA samples from 376 PCa patients. Their association with PCa prognostic factors, namely biochemical recurrence (BCR) and International Society of Urological Pathology (ISUP) grade was analyzed by generalized linear models and survival analyses., Result: Proportional hazards regression showed that the minor CD6 rs12360861
AA and CD166/ALCAM rs579565AA genotypes were associated with earlier BCR, with hazard ratios of 2.65 (95% CI: 1.39-5.05, p = 0.003) and 1.86, (95% CI: 1.02-3.39, p = 0.043), respectively. Individually, none of the analyzed SNPs was significantly associated with ISUP grade, but haplotype analyses revealed association of the CD5 rs2241002C -rs2229177T haplotype with ISUP grade ≥2, with odds ratio of 1.52 (95% CI: 1.05-2.21, p = 0.026)., Conclusion: The results show the impact on PCa aggressiveness and recurrence brought about by gene variants involved in modulation of lymphocyte activation (CD5, CD6) and immune-epithelial cell adhesion (CD166/ALCAM) in PCa aggressiveness and recurrence, thus supporting a role for host immune response in PCa pathophysiology., (© 2022 The Authors. The Prostate published by Wiley Periodicals LLC.)- Published
- 2022
- Full Text
- View/download PDF
5. Experimental and genetic evidence for the impact of CD5 and CD6 expression and variation in inflammatory bowel disease.
- Author
-
Casadó-Llombart S, Velasco-de Andrés M, Català C, Leyton-Pereira A, Gutiérrez-Cózar R, Suárez B, Armiger N, Carreras E, Esteller M, Ricart E, Ordás I, Gisbert JP, Chaparro M, Esteve M, Márquez L, Busquets D, Iglesias E, García-Planella E, Martín-Arranz MD, Lohmann J, Ayata CK, Niess JH, Engel P, Panés J, Salas A, Domènech E, and Lozano F
- Subjects
- Animals, Dextran Sulfate toxicity, Mice, Colitis chemically induced, Colitis, Ulcerative chemically induced, Colitis, Ulcerative genetics, Crohn Disease genetics, Inflammatory Bowel Diseases genetics
- Abstract
Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) resulting from the interaction of multiple environmental, genetic and immunological factors. CD5 and CD6 are paralogs encoding lymphocyte co-receptors involved in fine-tuning intracellular signals delivered upon antigen-specific recognition, microbial pattern recognition and cell adhesion. While CD5 and CD6 expression and variation is known to influence some immune-mediated inflammatory disorders, their role in IBD remains unclear. To this end, Cd5 - and Cd6 -deficient mice were subjected to dextran sulfate sodium (DSS)-induced colitis, the most widely used experimental animal model of IBD. The two mouse lines showed opposite results regarding body weight loss and disease activity index (DAI) changes following DSS-induced colitis, thus supporting Cd5 and Cd6 expression involvement in the pathophysiology of this experimental IBD model. Furthermore, DNA samples from IBD patients of the ENEIDA registry were used to test association of CD5 (rs2241002 and rs2229177) and CD6 (rs17824933, rs11230563, and rs12360861) single nucleotide polymorphisms with susceptibility and clinical parameters of CD (n=1352) and UC (n=1013). Generalized linear regression analyses showed association of CD5 variation with CD ileal location (rs2241002
CC ) and requirement of biological therapies (rs2241002C -rs2229177T haplotype), and with poor UC prognosis (rs2241002T -rs2229177T haplotype). Regarding CD6 , association was observed with CD ileal location (rs17824933G ) and poor prognosis (rs12360861G ), and with left-sided or extensive UC, and absence of ankylosing spondylitis in IBD (rs17824933G ). The present experimental and genetic evidence support a role for CD5 and CD6 expression and variation in IBD's clinical manifestations and therapeutic requirements, providing insight into its pathophysiology and broadening the relevance of both immunomodulatory receptors in immune-mediated disorders., Competing Interests: FL is founder and ad-honorem scientific advisor of Sepsia Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Casadó-Llombart, Velasco-de Andrés, Català, Leyton-Pereira, Gutiérrez-Cózar, Suárez, Armiger, Carreras, Esteller, Ricart, Ordás, Gisbert, Chaparro, Esteve, Márquez, Busquets, Iglesias, García-Planella, Martín-Arranz, Lohmann, Ayata, Niess, Engel, Panés, Salas, Domènech, Lozano and ENEIDA Project of GETECCU.)- Published
- 2022
- Full Text
- View/download PDF
6. Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.
- Author
-
Potrony M, Carreras E, Aranda F, Zimmer L, Puig-Butille JA, Tell-Martí G, Armiger N, Sucker A, Giménez-Xavier P, Martínez-Florensa M, Carrera C, Malvehy J, Schadendorf D, Puig S, and Lozano F
- Subjects
- Adult, CD5 Antigens metabolism, Female, Genotype, Germany epidemiology, Humans, Kaplan-Meier Estimate, Male, Melanoma epidemiology, Odds Ratio, Polymorphism, Single Nucleotide, Prognosis, Proportional Hazards Models, Retrospective Studies, Spain epidemiology, CD5 Antigens genetics, Genetic Variation, Melanoma etiology, Melanoma mortality, T-Lymphocytes immunology
- Abstract
Despite the recent progress in treatment options, malignant melanoma remains a deadly disease. Besides therapy, inherited factors might modulate clinical outcome, explaining in part widely varying survival rates. T-cell effector function regulators on antitumor immune responses could also influence survival. CD5, a T-cell receptor inhibitory molecule, contributes to the modulation of antimelanoma immune responses as deduced from genetically modified mouse models. The CD5 SNPs rs2241002 (NM_014207.3:c.671C > T, p.Pro224Leu) and rs2229177 (NM_014207.3:c.1412C > T, p.Ala471Val) constitute an ancestral haplotype (Pro224-Ala471) that confers T-cell hyper-responsiveness and worsens clinical autoimmune outcome. The assessment of these SNPs on survival impact from two melanoma patient cohorts (Barcelona, N = 493 and Essen, N = 215) reveals that p.Ala471 correlates with a better outcome (OR= 0.57, 95% CI = 0.33-0.99, Adj. p = 0.043, in Barcelona OR = 0.63, 95% CI = 0.40-1.01, Adj. p = 0.051, in Essen). While, p.Leu224 was associated with increased melanoma-associated mortality in both cohorts (OR = 1.87, 95% CI = 1.07-3.24, Adj. p = 0.030 in Barcelona and OR = 1.84, 95% CI = 1.04-3.26, Adj. p = 0.037, in Essen). Furthermore survival analyses showed that the Pro224-Ala471 haplotype in homozygosis improved melanoma survival in the entire set of patients (HR = 0.27, 95% CI 0.11-0.67, Adj. p = 0.005). These findings highlight the relevance of genetic variability in immune-related genes for clinical outcome in melanoma., (© 2016 UICC.)
- Published
- 2016
- Full Text
- View/download PDF
7. Etiopathogenic role of surfactant protein d in the clinical and immunological expression of primary Sjögren syndrome.
- Author
-
Soto-Cárdenas MJ, Gandía M, Brito-Zerón P, Arias MT, Armiger N, Bové A, Bosch X, Retamozo S, Akasbi M, Pérez-De-Lis M, Gueitasi H, Kostov B, Pérez-Alvarez R, Siso-Almirall A, Lozano F, and Ramos-Casals M
- Subjects
- Adult, Aged, Female, Genetic Predisposition to Disease, Humans, Immunity, Innate genetics, Male, Middle Aged, Pulmonary Surfactant-Associated Protein D blood, Sjogren's Syndrome blood, Sjogren's Syndrome immunology, Genotype, Polymorphism, Single Nucleotide, Pulmonary Surfactant-Associated Protein D genetics, Sjogren's Syndrome genetics
- Abstract
Objective: To analyze the etiopathogenic role of genetic polymorphisms and serum levels of surfactant protein-D (SP-D) in primary Sjögren syndrome (pSS)., Methods: We analyzed 210 consecutive patients with pSS. SFTPD genotyping (M11T polymorphism rs721917) was analyzed by sequence-based typing and serum SP-D by ELISA., Results: Thirty-two patients (15%) had the Thr11/Thr11 genotype, 80 (38%) the Met11/Met11 genotype, and 96 (46%) the Met11/Thr11 genotype; 2 patients could not be genotyped. Patients carrying the Thr11/Thr11 genotype had a higher prevalence of renal involvement (13% vs 1% and 4% in comparison with patients carrying the other genotypes, p = 0.014). Serum SP-D levels were analyzed in 119 patients (mean 733.94 ± 49.88 ng/ml). No significant association was found between serum SP-D levels and the SP-D genotypes. Higher mean values of serum SP-D were observed in patients with severe scintigraphic involvement (851.10 ± 685.69 vs 636.07 ± 315.93 ng/ml, p = 0.038), interstitial pulmonary disease (1053.60 ± 852.03 vs 700.36 ± 479.33 ng/ml, p = 0.029), renal involvement (1880.64 ± 1842.79 vs 716.42 ± 488.01 ng/ml, p = 0.002), leukopenia (899.83 ± 661.71 vs 673.13 ± 465.88 ng/ml, p = 0.038), positive anti-Ro/SS-A (927.26 ± 731.29 vs 642.75 ± 377.23 ng/ml, p = 0.006), and positive anti-La/SS-B (933.28 ± 689.63 vs 650.41 ± 428.14 ng/ml, p = 0.007), while lower mean values of serum SP-D were observed in patients with bronchiectasis (489.49 vs 788.81 ng/ml, p = 0.019)., Conclusion: In pSS, high SP-D levels were found in patients with severe glandular involvement, hypergammaglobulinemia, leukopenia, extraglandular manifestations, and positive anti-Ro/La antibodies. The specific association between SP-D levels and pulmonary and renal involvements may have pathophysiological implications.
- Published
- 2015
- Full Text
- View/download PDF
8. Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients.
- Author
-
Cenit MC, Martínez-Florensa M, Consuegra M, Bonet L, Carnero-Montoro E, Armiger N, Caballero-Baños M, Arias MT, Benitez D, Ortego-Centeno N, de Ramón E, Sabio JM, García-Hernández FJ, Tolosa C, Suárez A, González-Gay MA, Bosch E, Martín J, and Lozano F
- Subjects
- Alleles, Autoimmunity immunology, Case-Control Studies, Genetic Predisposition to Disease, Genotype, Humans, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic immunology, Lupus Nephritis diagnosis, CD5 Antigens genetics, Haplotypes genetics, Lupus Erythematosus, Systemic genetics, Lupus Nephritis etiology, Lymphocyte Activation immunology, Polymorphism, Genetic genetics, T-Lymphocytes immunology
- Abstract
Objective: CD5 plays a crucial role in autoimmunity and is a well-established genetic risk factor of developing RA. Recently, evidence of positive selection has been provided for the CD5 Pro224-Val471 haplotype in East Asian populations. The aim of the present work was to further analyze the functional relevance of non-synonymous CD5 polymorphisms conforming the ancestral and the newly derived haplotypes (Pro224-Ala471 and Pro224-Val471, respectively) as well as to investigate the potential role of CD5 on the development of SLE and/or SLE nephritis., Methods: The CD5 SNPs rs2241002 (C/T; Pro224Leu) and rs2229177 (C/T; Ala471Val) were genotyped using TaqMan allelic discrimination assays in a total of 1,324 controls and 681 SLE patients of Spanish origin. In vitro analysis of CD3-mediated T cell proliferative and cytokine response profiles of healthy volunteers homozygous for the above mentioned CD5 haplotypes were also analyzed., Results: T-cell proliferation and cytokine release were significantly increased showing a bias towards to a Th2 profile after CD3 cross-linking of peripheral mononuclear cells from healthy individuals homozygous for the ancestral Pro224-Ala471 (CC) haplotype, compared to the more recently derived Pro224-Val471 (CT). The same allelic combination was statistically associated with Lupus nephritis., Conclusion: The ancestral Ala471 CD5 allele confers lymphocyte hyper-responsiveness to TCR/CD3 cross-linking and is associated with nephritis in SLE patients.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.